64 search results for: symposium
ADVENT at UEG WEEK 2025 | Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care
Join Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, for an educational symposium as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression.
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
Identification and Management of AD Uncontrolled With Topical Therapies in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE).
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a Symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE). This event is neither sponsored by nor endorsed by ACG.
ADVENT at ESPGHAN 2025 | Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
In support of World Eosinophilic Esophagitis Day, this ADVENT symposium features pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
